Scarica l'app Stockscreener
76.06
3.72%
2.73
Dopo l'orario di chiusura:
78.47
2.41
+3.17%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld MedTech
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
Dwarfism meds 'miraculously' took kids who started at a low growth baseline to typical height velocity: BridgeBio Pharma CEO - Fox Business
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
BridgeBio reports positive phase 3 topline results for oral infigratinib - marketscreener.com
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing - MedCity News
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week HighHere's What Happened - MarketBeat
BridgeBio's oral drug improves growth in children with dwarfism in late-stage study - marketscreener.com
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? - Stocktwits
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BridgeBio (BBIO) Surges on Positive Phase 3 Results for Infigrat - GuruFocus
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
Positive Phase III top-line results for BridgeBio’s oral infigratinib - The Pharma Letter
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
BridgeBio Pharma stock price target raised to $89 at Raymond James on positive trial data - Investing.com Canada
BridgeBio Pharma stock hits all-time high at 84.51 USD - Investing.com
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - MarketBeat
BridgeBio posts trial win for dwarfism drug (BBIO:NASDAQ) - Seeking Alpha
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com Canada
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - The Manila Times
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com Canada
BridgeBio Pharma Reports Positive Topline Results from PROPEL 3 Study of Oral Infigratinib in Children with Achondroplasia - Quiver Quantitative
BBIO: Oral infigratinib delivers significant growth and proportionality benefits in achondroplasia - TradingView
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Candriam S.C.A. Invests $7.74 Million in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma supports LGMD Family Guide distribution at conference - Traders Union
Targets Report: What are the analyst revisions for NSTSIs BridgeBio Pharma Inc stock a good investment in YEARJuly 2025 Decliners & Fast Gain Stock Trading Tips - baoquankhu1.vn
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Buy the Dip on This Biotech Stock After Recent Fall - Finviz
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? - Yahoo Finance
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection (NASDAQ:BBIO) - Seeking Alpha
Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO), Bristol-Myers Squibb (BMY) and Qiagen (QGEN) - The Globe and Mail
BridgeBio (BBIO) tumbles 15%, mirrors marked bleed - MSN
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap UpHere's What Happened - MarketBeat
BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed - Finviz
BridgeBio Pharma Enters Oversold Territory (BBIO) - Nasdaq
WCM Investment Management LLC Sells 14,253 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Principal Financial Group Inc. - MarketBeat
Y Intercept Hong Kong Ltd Has $724,000 Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Eyeing a 20.55% Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (BBIO) - Stock Traders Daily
Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT - MSN
BridgeBio Pharma, Inc. $BBIO Shares Acquired by Federated Hermes Inc. - MarketBeat
Movement Recap: Is BridgeBio Pharma Inc stock a value trapJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Assessing BridgeBio Pharma (BBIO) Valuation After Recent Share Price Volatility - Yahoo Finance
Barclays Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight Recommendation - Nasdaq
Will BridgeBio Pharma Inc. benefit from government policyGold Moves & Free Fast Gain Swing Trade Alerts - mfd.ru
BBIO Sees New Analyst Initiation with 'Overweight' Rating by Bar - GuruFocus
Barclays Initiates Coverage on BridgeBio Pharma With Overweight Rating, $157 Price Target - marketscreener.com
BridgeBio Pharma stock initiated with Overweight rating by Barclays - Investing.com Canada
Barclays Begins Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):